A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

Hemophilia A Clinical Trial

Official title:

A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02035605
• Other study ID #: ALN-AT3SC-001
• Status: Completed
• Phase: Phase 1
• Start date: January 20, 2014
• Est. completion date: July 20, 2017

Study information

• Verified date: June 2018
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of ALN-AT3SC in healthy volunteers and Hemophilia A or B patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: July 20, 2017
• Est. primary completion date: July 20, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Part A (SAD phase) inclusion:

• Healthy adult males aged 18 to 40 years inclusive at Screening.

• Subjects with adequate complete blood counts and liver function tests.

• Willing to provide written informed consent and willing to comply with study requirements.

Part B & C (MAD & MD phase) inclusion:

• Adult male hemophilia patients aged 18 to 65 years inclusive at Screening.

• Patients with adequate complete blood counts and liver function tests.

• Patients with moderate or severe, clinically stable hemophilia A or B (Factor VIII or Factor IX =5%).

• Willing to provide written informed consent and willing to comply with study requirements

Part D (MD Phase in patients with inhibitors) Inclusion:

• Same as Parts B/C

• A Bethesda inhibitor assay > 0.6 BU/mL

Exclusion Criteria:

Part A (SAD phase) exclusion:

• Subjects with a personal history and/or family history of venous thromboembolism (VTE)

• Subjects with a known co-existing thrombophilic disorder

• Subjects with a history of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc.

• Subjects with a history of serious mental illness that includes, but is not limited to schizophrenia, bipolar disorder, severe depression requiring hospitalization or pharmacological intervention.

• Subjects who have a clinically relevant history or presence of cardiovascular, respiratory, gastrointestinal, renal, hematological, lymphatic, neurological, musculoskeletal, genitourinary, immunological including osteoarthritis and other inflammatory diseases, dermatological including rash, eczema, dermatitis, or connective tissue diseases or disorders.

Part B & C (MAD & MD phase) exclusion:

• Patients with a current serious mental illness that, in the judgment of the Investigator, may compromise patient safety, ability to participate in all study assessments, or study integrity.

• Patients who have a clinically relevant history or presence of cardiovascular, respiratory, gastrointestinal, renal, neurological, inflammatory or other diseases that in the judgment of the investigator precludes their participation in the study.

• Patients with a known co-existing thrombophilic disorder

• Patients with a history of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc.

• Patients who are known to be HIV positive and have a CD4 count <400 cells/µL

Part D (MD Phase in patients with inhibitors) exclusion:

• Same as Parts B/C

• Patients who are known to be HIV positive and have a CD4 count <200 cells/µL

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia B

Intervention

Drug:
• ALN-AT3SC
Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
• Sterile Normal Saline (0.9% NaCl)
Calculated volume to match active comparator

Locations

Country	Name	City	State
Bulgaria	Clinical Trial Site	Plovdiv
Bulgaria	Clinical Trial Site	Sofia
Bulgaria	Clinical Trial Site	Varna
Russian Federation	Clinical Trial Site	Kirov
Russian Federation	Clinical Trial Site	Moscow
Russian Federation	Clinical Trial Site	St. Petersburg
Switzerland	Clinical Trial Site	St. Gallen
Switzerland	Clinical Trial Site	Zurich
United Kingdom	Clinical Trial Site	Glasgow
United Kingdom	Clinical Trial Site	London
United Kingdom	Clinical Trial Site	London
United Kingdom	Clinical Trial Site	Manchester
United Kingdom	Clinical Trial Site	Truro
United States	Clinical Trial Site	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Bulgaria,  Russian Federation,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The safety of ALN-AT3SC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and AEs leading to study drug discontinuation.		Part A (SAD phase): through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112
Secondary	The pharmacokinetics (PK) of ALN-AT3SC as characterized by plasma PK profiles and urine samples.		Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112
Secondary	The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma AT levels.		Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112
Secondary	The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma TG.		Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70; Part C (MD Phase) through Day 112; Part D (MD Phase in patients with inhibitors) through Day 112